Astonea Labs Limited
Bookbuilding IPO · BSE
- Price band
- ₹128 - ₹135
- Lot size
- 1,000 shares
- Issue amount
- ₹37.67 cr
- Total subscription
- 2.55×
- Opens
- 27 May 2025
- Closes
- 29 May 2025
- Allotment
- 30 May 2025
- Listing
- 3 Jun 2025
Offer at a glance
Issue overview
- Issue size
- 27,90,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,28,000
- Fresh issue
- ₹37.67 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,35,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 77,21,000
- Shares after issue
- 1,05,11,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 1,000 | ₹1,35,000 |
| HNI | 2 | 2,000 | ₹2,70,000 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 17.82 | 0 |
| RETAIL | 12.51 | 0.39 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 5.32 | 5.01 | 0.88 |
| ROE | 28.06 | 37.86 | 8.5 |
| ROCE | 18.34 | 22.95 | 10.83 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 27.36 | 0 |
| POST IPO(PE) | 25.94 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Astonea Labs Ltd., established in 2017, is engaged in the contract manufacturing of pharmaceutical and cosmetic products for both Indian and international companies. The company produces a wide range of medicines, including antibiotics and treatments for colds, infections, diabetes, heart conditions, and gynecological issues. It also manufactures skincare, haircare, and dental care products in the form of gels, creams, and serums. In addition to manufacturing, Astonea Labs provides packaging and raw materials to other pharmaceutical and cosmetic companies, adhering to industry standards. The company markets its own brands—Glow Up, a dermo-cosmetic line, and Regero, a pharmaceutical range—and is preparing to launch a new brand named Avicel. It also exports products to countries like Iraq and Yemen. As of August 16, 2024, the company had 217 employees on its payroll.
Strengths
- Wide Range of Products: Provides various pharma and cosmetic products in both health and personal care categories.
- Two Business Models: Earns revenue through its own brands and by manufacturing for other companies.
- Global Reach: Exports products to countries like Iraq and Yemen, helping diversify income from different regions.
Risk factors
- Regulatory Issues: Missing FDA fee payments and delays in filings may lead to penalties and extra regulatory checks.
- Heavy Reliance on Few Suppliers: Most raw materials are sourced from the top 10 suppliers—any issues with them can affect production.
- Third-Party Risks: Depending on external suppliers may cause delays, quality problems, or contract-related issues.
Promoters
Ashish Gulati
Registrar & documents
Lead manager
Oneview Corporate Advisors Private limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
House No. 1358, 1st Floor, Sector-22B
+91 9888302323
[email protected]Company website ↗Understanding ASTONEALAB IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.